@inproceedings{cottron:hal-03687586,
TITLE = {Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study},
AUTHOR = {Cottron, C. and Treton, X. and Altwegg, R. and Reenaers, C. and Amiot, A. and Fumery, Mathurin and Vuitton, L. and Peyrin-Biroulet, L. and Bouguen, G. and Dewit, O. and Nancey, S. and Caillo, L. and Roblin, X. and Beylot-Barry, M. and Riviere, P. and Laharie, D.},
URL = {https://hal.science/hal-03687586},
BOOK
TITLE = {17th Congress of ECCO},
ADDRESS = {Vienna, Austria},
VOLUME = {16},
NUMBER = {Supplement\_1},
PAGES = {I502-I502},
YEAR = {2022},
MONTH = Feb, DOI = {10.1093/ecco-jcc/jjab232.684},
HAL_ID = {hal-03687586},
HAL_VERSION = {v1},
}